Management of vitiligo: clinical experience with topical ruxolitinib

Vitiligo is a chronic autoimmune skin disorder with profound psychological and social consequences, as depigmented lesions are highly visible and often stigmatising. Until recently, therapeutic options were limited, and many patients were informed that no effective treatment was available. The introduction of topical ruxolitinib, a JAK inhibitor, has opened new perspectives for disease management. While reimbursement was only recently approved in Belgium, dermatologists in Luxembourg have already gained experience with this therapy, offering valuable clinical insights. Prof Reinhart Speackaert, dermatologist from UZ Gent interviews Dr Florence Bourlond, dermatologist in Luxembourg about her clinical experience with topical ruxolitinib

Initial clinical experiences are highly encouraging, with patients frequently reporting visible repigmentation after approximately six months of treatment. Emotional responses are striking, as the restoration of pigmentation significantly reduces disease burden and improves quality of life. 

In practice, treatment is generally initiated on the face, given its visibility and responsiveness. If satisfactory results are achieved after three to six months, therapy may be extended to other sites, such as the hands. Whole-body application remains impractical due to the limited coverage area of the cream. Patient adherence is supported by structured follow-up visits, typically at three months to reinforce motivation and at six months to evaluate efficacy. Photographic documentation at baseline and subsequent visits is considered essential to objectively demonstrate treatment progress, as patients may underestimate gradual changes.

Adverse events are minimal, with only mild local irritation or acneiform eruptions occasionally observed. Importantly, these events are not consistently attributable to ruxolitinib and are comparable to those seen with conventional therapies, such as corticosteroids. Overall, tolerability in daily clinical practice appears excellent, supporting sustained patient adherence.

Treatment positioning differs between countries. In Belgium, reimbursement currently requires prior failure of at least six months of topical therapy, whereas in Luxembourg no such restrictions exist. Consequently, many dermatologists in Luxembourg employ ruxolitinib as a first-line option, particularly for localised facial disease, citing its efficacy and favourable safety profile. While cost remains a consideration, limited application to small areas makes it manageable in practice.

The availability of ruxolitinib is gradually transforming medical perspectives on vitiligo. While dermatologists increasingly recognise its therapeutic relevance, broader awareness among general practitioners and paediatricians remains essential to ensure timely referral. 

Looking ahead, further comparative studies, particularly head-to-head trials against existing therapies such as tacrolimus, will be valuable to define its optimal place in treatment algorithms. Nevertheless, current evidence and clinical experience strongly suggest that topical ruxolitinib represents a major advance in vitiligo care.